Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285
Conditions
Obesity
Interventions
Galantamine, Placebo Oral Capsule, Intralipid, Heparin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid), PP1M 50 mg eq., PP1M 75 mg eq., PP1M 100 mg eq., PP1M 150 mg eq.
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
24
States / cities
Little Rock, Arkansas • Glendale, California • Long Beach, California + 21 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

NCT02406586
Conditions
Hypertension, Diabetes
Interventions
Salsalate, Carvedilol, Placebo, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Dyspnea, Hypertension, Acute Heart Failure
Interventions
Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Increased Free Fatty Acids on Leptin Function

NCT01520454
Conditions
Obesity, Leptin Resistance
Interventions
Saline, Intralipid, Water, oral fat, Heparin
Drug · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Schizophrenia
Interventions
Placebo, Paliperidone Palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
18
States / cities
Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more
Conditions
Obesity
Interventions
Intralipid, 20% Intravenous Emulsion, Placebos
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid emulsion)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Little Rock, Arkansas • San Fran Cisco, California • Washington D.C., District of Columbia + 12 more
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Traumatic Brain Injury
Interventions
Progesterone, Placebo
Drug
Lead sponsor
David Wright
Other
Eligibility
18 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tuscon, Arizona + 26 more